Literature DB >> 26843355

In-hospital outcomes in patients with critical limb ischemia and end-stage renal disease after revascularization.

Alexander Meyer1, Werner Lang2, Matthias Borowski3, Giovanni Torsello4, Theodosios Bisdas4.   

Abstract

OBJECTIVE: Analysis of in-hospital outcomes in patients treated for critical limb ischemia (CLI) and end-stage renal disease (ESRD) compared to CLI patients with normal renal function.
METHODS: A subgroup analysis of the German CRITISCH registry, a prospective multicenter registry, assessing the first-line treatment strategies in CLI patients in 27 vascular centers in Germany was performed. The study cohort was divided into ESRD patients (n = 102) and patients with normal renal function (n = 674; glomerular filtration rate >60/mL/min/1.73 m(2)). The following first-line treatment strategies were assessed: endovascular therapy (EVT), bypass surgery, patch plasty, and no vascular intervention (conservative treatment, primary amputation). Uni- and multivariate analyses were performed to identify differences between groups as to six end points: amputation or death (composite end point), amputation, death, hemodynamic failure, major adverse cardiac and cerebrovascular events, and reintervention.
RESULTS: Differences between the ESRD and non-ESRD group were found regarding the applied first-line therapy (P = .016): The first-line treatment strategies in ESRD patients were EVT in 64% (n = 65), bypass surgery in 13% (n = 13), patch plasty in 11% (n = 11), and no vascular intervention in 13% (n = 13). In non-ESRD patients, EVT was applied in 48% (n = 326), bypass surgery in 27% (n = 185), patch plasty in 13% (n = 86), and no vascular intervention in 11% (n = 77). For ESRD patients, a noticeably increased risk of the composite end point (odds ratio [OR], 2.62; 95% confidence interval [CI], 1.19-5.79; P = .017), amputation (OR, 3.14; 95% CI, 1.35-7.31; P = .008), and hemodynamic failure (OR, 2.19; 95% CI, 1.19-4.04; P = .012) was observed.
CONCLUSIONS: CLI patients on dialysis represent a challenging cohort prone to in-hospital death, amputation, and hemodynamic failure. Two-thirds of these high-risk patients are treated with EVT. Present data suggest that this modality is generally considered as the most favorable treatment option in this patient subgroup.
Copyright © 2016 Society for Vascular Surgery. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2016        PMID: 26843355     DOI: 10.1016/j.jvs.2015.10.009

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  10 in total

1.  Clinical significance of perioperative changes in ankle-brachial index with regard to extremity-related outcome in non-diabetic patients with critical limb ischemia.

Authors:  Moritz S Bischoff; K Meisenbacher; A S Peters; D Weber; T Bisdas; G Torsello; D Böckler
Journal:  Langenbecks Arch Surg       Date:  2018-06-17       Impact factor: 3.445

2.  Two-year clinical outcomes following lower limb endovascular revascularisation for chronic limb-threatening ischaemia at a tertiary Asian vascular centre in Singapore.

Authors:  Wei Ling Tay; Tze Tec Chong; Sze Ling Chan; Hao Yun Yap; Kiang Hiong Tay; Marcus Eng Hock Ong; Edward Tieng Chek Choke; Tjun Yip Tang
Journal:  Singapore Med J       Date:  2020-07-16       Impact factor: 3.331

3.  Nationwide Trends in Hospital Outcomes and Utilization After Lower Limb Revascularization in Patients on Hemodialysis.

Authors:  Pranav S Garimella; Poojitha Balakrishnan; Ashish Correa; Priti Poojary; Narender Annapureddy; Kinsuk Chauhan; Achint Patel; Shanti Patel; Ioannis Konstantinidis; Lili Chan; Shiv Kumar Agarwal; Bernard G Jaar; Umesh Gidwani; Kunihiro Matsushita; Girish N Nadkarni
Journal:  JACC Cardiovasc Interv       Date:  2017-10-23       Impact factor: 11.195

4.  Predictors of early mortality and readmissions among dialysis patients undergoing lower extremity amputation.

Authors:  LaTonya J Hickson; Andrew D Rule; Bjorg Thorsteinsdottir; Raymond C Shields; Ivan E Porter; Mark D Fleming; Daniel S Ubl; Cynthia S Crowson; Kristine T Hanson; Bassem T Elhassan; Rajnish Mehrotra; Shipra Arya; Robert C Albright; Amy W Williams; Elizabeth B Habermann
Journal:  J Vasc Surg       Date:  2018-06-28       Impact factor: 4.268

Review 5.  Current Perspective on Hemodialysis Patients with Peripheral Artery Disease.

Authors:  Shin Okamoto; Osamu Iida; Toshiaki Mano
Journal:  Ann Vasc Dis       Date:  2017-06-25

Review 6.  Hybrid Operations in Patients with Peripheral Arterial Disease.

Authors:  Atsubumi Murakami
Journal:  Ann Vasc Dis       Date:  2018-03-25

7.  Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.

Authors:  Yukihisa Ogawa; Hiroyoshi Yokoi; Takao Ohki; Kimihiko Kichikawa; Masato Nakamura; Kimihiro Komori; Shinsuke Nanto; Erin E O'Leary; Aaron E Lottes; Alan T Saunders; Michael D Dake
Journal:  Cardiovasc Intervent Radiol       Date:  2017-05-09       Impact factor: 2.740

Review 8.  Outcomes of Lower Extremity Endovascular Revascularization: Potential Predictors and Prevention Strategies.

Authors:  Federico Biscetti; Elisabetta Nardella; Maria Margherita Rando; Andrea Leonardo Cecchini; Antonio Gasbarrini; Massimo Massetti; Andrea Flex
Journal:  Int J Mol Sci       Date:  2021-02-18       Impact factor: 5.923

9.  The Impact of Chronic Kidney Disease on Mid-Term Outcomes after Revascularisation of Peripheral Arterial Occlusive Disease: Results from a Prospective Cohort Study.

Authors:  Artur Kotov; Deven A Blasche; Frederik Peters; Philip Pospiech; Ulrich Rother; Konstantinos Stavroulakis; Jürgen Remig; Christian Schmidt-Lauber; Thomas Zeller; Hartmut Görtz; Jörg Teßarek; Christian-Alexander Behrendt
Journal:  J Clin Med       Date:  2022-08-14       Impact factor: 4.964

10.  Bypass surgery versus endovascular intervention for lower extremity revascularization in patients with chronic renal disease or end-stage renal disease: a systematic review and meta-analysis.

Authors:  Yan Sun; Xiaojing Zhou; Jinmei Zhang
Journal:  Int Urol Nephrol       Date:  2021-07-07       Impact factor: 2.370

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.